Nedosiran
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics.
Journal: Molecular therapy. Nucleic acids
Published: December 19, 2025
The oxalobiome: unraveling the role of gut microbiota in oxalate metabolism and its implications for kidney health and disease management.
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: December 17, 2025
Comparative evaluation of ultrafiltration and EMSA formats for siRNA plasma protein binding: Methodological determinants and artifacts.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: December 17, 2025
Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.
Journal: Frontiers in pharmacology
Published: October 07, 2025
Isolated Kidney Transplant in Primary Hyperoxaluria-1 Enabled by Small Interfering RNA (siRNA) Therapy. Is It Time for Change? Case Report and Review of the Literature.
Journal: Pediatric transplantation
Published: September 11, 2025
Primary hyperoxaluria(s): from trials to real-life data and pipeline therapies.
Journal: Kidney international
Published: July 29, 2025
Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation for Nedosiran Clinical Development and Dose Guidance in Pediatric Patients with Primary Hyperoxaluria Type 1.
Journal: Clinical pharmacokinetics
Published: June 05, 2025
RNA interference medication and transplantation procedures in patients with primary hyperoxaluria type 1.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: April 07, 2025
Primary Hyperoxaluria Type 1: An Unexpected Diagnosis after Kidney Transplantation.
Journal: Kidney & blood pressure research
Published: March 09, 2025
Development, opportunities, and challenges of siRNA nucleic acid drugs.
Journal: Molecular therapy. Nucleic acids
Published: February 03, 2025
PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1.
Journal: Kidney international reports
Published: December 20, 2024
Concomitant Treatment With Lumasiran and Nedosiran in a Child With Primary Hyperoxaluria Type 1.
Journal: Kidney international reports
Published: December 02, 2024
Last Updated: 06/30/2026